Search hospitals > Oregon > Bend
Saint Charles Health System
Claim this profileBend, Oregon 97701
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
Conducts research for Recurrence
294 reported clinical trials
8 medical researchers
Summary
Saint Charles Health System is a medical facility located in Bend, Oregon. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Saint Charles Health System is involved with conducting 294 clinical trials across 465 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
101 reported clinical trials
178 drugs studied
Charles W. DrescherProvidence Portland Medical Center7 years of reported clinical research
Expert in Cancer
Studies Tumors
46 reported clinical trials
87 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
26 reported clinical trials
63 drugs studied
Clinical Trials running at Saint Charles Health System
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Pancreatic Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Pancreatic Carcinoma
Multiple Myeloma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Charles Health System?
Saint Charles Health System is a medical facility located in Bend, Oregon. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Saint Charles Health System is involved with conducting 294 clinical trials across 465 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.